Baili Tianheng secures three Breakthrough Therapy designations and blood-cancer ADC trial approval in China
On September 27, Chinese biopharmaceutical company Baili Tianheng announced that three of its antibody-drug conjugates—iza-bren, BL-M05D1, and T-Bren—were granted Breakthrough Therapy Designation by China's NMPA for biliary tract and gastric cancers. Separately, the NMPA approved a clinical trial for BL-M12D1, an ADC targeting relapsed or refractory hematologic malignancies, marking the company's expansion beyond solid tumors. A global Phase III trial for iza-bren triggered a $250 million milestone payment from Bristol Myers Squibb.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Baili Tianheng has a promising platform with multiple drug candidates that have received breakthrough therapy designations from China's NMPA.
- Phase III data is the ultimate test to confirm whether these drugs work better than current treatments.
- The $1.3 billion in milestone payments from BMS shows that a major global pharma company sees real potential in the platform.
- The company is not a one-drug company, as it has distinct candidates like BL-M05D1, BL-M12D1, and T-Bren targeting different cancers.
Points of contention
- The Eastern agent sees nine breakthrough designations as strong evidence of a proven platform, while the neutral agent says regulatory recognition is not the same as clinical proof.
- The Eastern agent argues China's NMPA is as rigorous as the FDA, but the neutral agent says the NMPA's system is newer and less tested, so its designations are less certain to lead to approval.
- The Eastern agent believes the platform model is validated by past successes like Seagen and ImmunoGen, while the neutral agent points out those companies had approved drugs first, which Baili Tianheng lacks.
- The Eastern agent frames this as a shift in global pharmaceutical power, but the neutral agent says that geopolitical framing distracts from the scientific question of whether the drugs work in trials.
Blind spots
- Both sides focus on scientific and regulatory risks but underplay the commercial risk of creating a new drug category for EGFR×HER3 bispecific ADCs, where the market is undefined.
- Neither side fully addresses how the NMPA's shorter track record affects the reliability of its breakthrough designations compared to the FDA's longer history.
- The debate overlooks the possibility that even if the platform works, high sales hurdles could prevent the full $8.4 billion from BMS from ever being paid out.
WorldAttention’s read
Baili Tianheng has built a promising ADC platform that has earned nine breakthrough therapy designations from China's NMPA for multiple drug candidates, and the BMS deal shows global pharma is betting on its potential. However, the company has zero approved products, and all its data so far comes from early-phase trials. The real test will be Phase III results, especially for BL-M05D1 in gastric cancer, which will show if these drugs can beat current standards of care. Until then, calling it a 'multi-core' strategy is premature, but dismissing it as a one-drug company ignores the platform's consistent regulatory signals. The smartest view is cautious optimism: the platform is real, but the proof is still ahead.
Reporting timeline
Baili Tianheng Gets Three ADC Breakthrough Therapy Designations, Expands Pipeline
On September 27, Chinese biopharmaceutical company Baili Tianheng announced that three of its innovative antibody-drug conjugates (ADCs) were included in China's Breakthrough Therapy Designation list. The drugs are: iza-bren (BL-B01D1) for biliary tract cancer, BL-M05D1 for advanced gastric cancer, and T-Bren for HER2-expressing biliary tract cancer. Iza-bren received its ninth breakthrough designation, adding biliary tract cancer to its existing approvals for nasopharyngeal and esophageal cancers. Separately, the company's BL-M12D1 ADC received clinical trial approval for blood cancers, marking an expansion beyond solid tumors. Industry analysts view these developments as evidence of Baili Tianheng's transition from a single-drug strategy to a multi-pipeline matrix, leveraging its proprietary ADC platform. The company also noted that a global Phase III trial for iza-bren triggered a $250 million milestone payment from Bristol Myers Squibb under a 2023 licensing deal with a potential total value of $8.4 billion. Baili Tianheng expects multiple ADCs to be approved in the next 2-3 years.
Read sourceBaili Tianheng Gets China NMPA Approval for Blood Cancer ADC Trial
Baili Tianheng (688506.SH) announced on September 27 that it has received a Drug Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for its independently developed innovative biologic, BL-M12D1 (ADC), for injection. The approval, under acceptance number CXSL2600763 and notice number 2026LP02948, authorizes the applicant—Chengdu Baili Duote Biological Pharmaceutical Co., Ltd. and Sichuan Baili Pharmaceutical Co., Ltd.—to conduct a single-agent clinical trial in patients with relapsed or refractory hematologic malignancies. The decision was based on a review under the Drug Administration Law of the People's Republic of China, concluding that the clinical trial application meets relevant drug registration requirements.
Read sourceBaili Tianheng's Innovative Biologic T-Bren Included in Breakthrough Therapy List
According to a report from People's Financial News on September 27, Baili Tianheng announced that it has received a formal 'Drug Clinical Trial Approval Notice' from China's National Medical Products Administration (NMPA). The approval is for the company's self-developed innovative biologic drug, injection BL-M12D1 (an ADC). This ADC drug is developed on the same technology platform as iza-bren and shares the same 'linker+toxin' platform as Yizekang. The approved indication is for relapsed or refractory hematologic malignancies. The news was sourced from Securities Times.
Read sourceShow 3 older updatesHide older updates
Baili Tianheng's BL-M05D1 Gets Breakthrough Therapy Designation for Gastric Cancer
Baili Tianheng (百利天恒) announced that its self-developed innovative biologic drug, BL-M05D1 (Claudin18.2 ADC), has been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration. The designation is for the treatment of patients with CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have received prior first-line standard therapy. BL-M05D1 is a novel antibody-drug conjugate targeting Claudin18.2. The company is currently conducting three clinical trials for the drug both domestically and internationally, with the Phase III clinical trial having completed enrollment of its first subject in June 2026. The company noted that drug development is subject to uncertainties due to technical, regulatory, and other factors.
Read sourceBaili Tianheng's BL-M05D1 Gets Breakthrough Therapy Designation for Gastric Cancer
Baili Tianheng (688506.SH) announced on September 27 that its self-developed innovative biologic, BL-M05D1 (Claudin18.2 ADC), has been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration. The designation is for the treatment of patients with CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received prior first-line standard therapy. This regulatory status is intended to expedite the development and review of promising new drugs for serious conditions.
Read sourceBaili Tianheng's Innovative Biologics T-Bren and Others Granted Breakthrough Therapy Designation in China
Baili Tianheng (688506) announced on September 27 that three of its self-developed innovative biologics have been included in the National Medical Products Administration's (NMPA) Center for Drug Evaluation's Breakthrough Therapy Designation list. These include T-Bren (HER2 ADC) for HER2-expressing locally advanced or metastatic biliary tract cancer patients who failed platinum-containing chemotherapy; BL-M05D1 (Claudin18.2 ADC) for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma patients after first-line standard therapy; and iza-bren (BL-B01D1), a first-in-class, globally first and only approved EGFR×HER3 bispecific antibody ADC, for recurrent or metastatic biliary tract cancer after platinum-containing chemotherapy. Separately, Baili Tianheng received NMPA approval for a clinical trial of BL-M12D1 (ADC), a drug sharing the same technology platform and 'linker+toxin' platform as iza-bren, for relapsed or refractory hematologic malignancies.
Read source